9,150 Shares in Johnson & Johnson $JNJ Bought by Marshall Investment Management LLC

Key Points

• Marshall Investment Management LLC acquired a new stake of 9,150 shares of Johnson & Johnson (NYSE: JNJ) in Q3, valued at about $1.697 million, according to its latest 13F filing.
• Institutional ownership is high at 69.55%, with major moves including Vanguard boosting its holding to 237,047,859 shares and Norges Bank establishing a new position worth roughly $4.88 billion, while Wellington, BNY Mellon and Legal & General also increased stakes.
• Insiders have been net sellers recently — 30,142 shares worth $7.36 million were sold in the past three months, including recent sales by EVPs Vanessa Broadhurst and Timothy Schmid.

Marshall Investment Management LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 9,150 shares of the company's stock, valued at approximately $1,697,000.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company's stock valued at $36,209,060,000 after acquiring an additional 3,085,180 shares during the last quarter. Norges Bank bought a new position in shares of Johnson & Johnson in the second quarter worth approximately $4,877,174,000. Wellington Management Group LLP raised its stake in Johnson & Johnson by 3.8% in the third quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company's stock valued at $4,789,914,000 after purchasing an additional 956,239 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Johnson & Johnson by 3.5% during the third quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company's stock valued at $4,568,313,000 after purchasing an additional 835,146 shares during the last quarter. Finally, Legal & General Group Plc grew its stake in Johnson & Johnson by 2.8% in the 3rd quarter. Legal & General Group Plc now owns 19,450,064 shares of the company's stock worth $3,606,431,000 after buying an additional 532,790 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares of the company's stock, valued at $5,598,700.17. The trade was a 21.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at approximately $6,251,310.02. This trade represents a 4.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $243.03 on Tuesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $251.71. The company has a fifty day moving average of $232.69 and a 200-day moving average of $207.13. The stock has a market capitalization of $585.37 billion, a price-to-earnings ratio of 21.99, a price-to-earnings-growth ratio of 2.38 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion for the quarter. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were issued a $1.30 dividend. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson's payout ratio is currently 47.06%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on JNJ. Argus raised their price objective on shares of Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. Bank of America reiterated a "neutral" rating on shares of Johnson & Johnson in a research report on Monday, March 2nd. Wolfe Research raised their price target on Johnson & Johnson from $225.00 to $240.00 and gave the company an "outperform" rating in a research report on Monday, January 5th. TD Cowen lifted their price target on Johnson & Johnson from $222.00 to $250.00 and gave the stock a "buy" rating in a research note on Thursday, January 22nd. Finally, UBS Group reiterated a "buy" rating on shares of Johnson & Johnson in a report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $235.91.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.